Background: With the development of coronavirus disease-2019 (COVID-19) pandemic, there is also increased risk of multiple secondary infections either disease- or drug-related. It includes many bacterial as well as invasive fungal infections. Patients and methods: There was suspicion of invasive pulmonary aspergillosis (IPA) infection in COVID-19 patients who were critically ill and had acute respiratory distress syndrome (ARDS). We did radiological evaluation and galactomannan assay in these patients. Result: We have diagnosed COVID-19-associated pulmonary aspergillosis (CAPA) in these patients and started antifungal treatment with voriconazole in all of these COVID-19 patients. Conclusion: It is very important to report such cases, so that healthcare professionals and authorities related to healthcare will be aware of and may also prepare for the increasing burden of this complication. We describe a case series of CAPA infection.
Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study. Lancet 2020;395(10229): 1054–1062. DOI: 10.1016/S0140-6736(20)30566-3.
Blanchard E, Gabriel F, Jeanne-Leroyer C, Servant V, Dumas PY. Invasive pulmonary aspergillosis. Rev Mal Respir 2018;35(2):171–187. DOI: 10.1016/j.rmr.2018.01.002.
Nasa P, Yadav R, Nagrani SK, Raina S, Gupta A, Jain S. Invasive pulmonary aspergillosis in an immunocompetent patient with severe dengue fever. Indian J Crit Care Med 2014;18(5):323–325. DOI: 10.4103/0972-5229.132505.
Schauwvlieghe AFAD, Rijnders BJA, Philips N, Verwijs R, Vanderbeke L, Tienen CV, et al. Invasive aspergillosis in patients admitted to the intensive care unit with severe influenza: a retrospective cohort study. Lancet Respir Med 2018;6(10):782–792. DOI: 10.1016/S2213-2600(18)30274-1.
Vanderbeke L, Spriet I, Breynaert C, Rijnders BJA, Verweij PE, Wauters J. Invasive pulmonary aspergillosis complicating severe infuenza: Epidemiology, diagnosis and treatment. Curr Opin Infect Dis 2018;31(6):471–480. DOI: 10.1097/QCO.0000000000000504.
Blot S, Rello J, Koulenti D. Diagnosing invasive pulmonary aspergillosis in ICU patients: Putting the puzzle together. Curr Opin Crit Care 2019;25(5):430–437. DOI: 10.1097/MCC.0000000000000637.
Jamieson AM, Yu S, Annicelli CH, Medzhitov R. Influenza virus-induced glucocorticoids compromise innate host defense against a secondary bacterial infection. Cell Host Microbe 2010;7(2):103–114. DOI: 10.1016/j.chom.2010.01.010.
Corman VM, Landt O, Kaiser M, Molenkamp R, Meijer A, Kw Chu D, et al. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. Euro Surveill 2020;25(3):2000045. DOI: 10.2807/1560- 7917.ES.2020.25.3.2000045.
Koehler P, Bassetti M, Kochanek M, Shimabukuro-Vornhagen A, Cornely OA. Intensive care management of influenza-associated pulmonary aspergillosis. Clin Microbiol Infect 2019;25(12):1501–1509. DOI: 10.1016/j.cmi.2019.04.031.
Koehler P, Bassetti M, Chakrabarti A, Chen SCA, Colombo AL, Hoenigl M, et al. Defining and managing COVID-19-associated pulmonary aspergillosis: The 2020 ECMM/ISHAM consensus criteria for research and clinical guidance. Lancet Infect Dis 2021;21(6): e149–e162. DOI: 10.1016/S1473-3099(20)30847-1.
Govil D, Kumar PG. Early CT in COVID-19: Should i or should i not. Indian J Crit Care Med 2021;25(3):251–252. DOI: 10.5005/jp-journals-10071-23772.
Bassetti M, Scudeller L, Giacobbe DR, Lamoth F, Righi E, Zuccaro V, et al. Developing definitions for invasive fungal disease in critically ill adult patients in intensive care units. Mycoses 2019;62(4):310–319. DOI: 10.1111/myc.12869.